The company presented 18-month data at a conference that it thinks will support strong uptake. European regulators required the 18-month data for filing; an FDA decision based on 9-month data is expected in April.

The rate at which investigational drugs were accepted onto the European Medicines Agency’s priority medicines scheme dropped in 2021. Meanwhile, more much-needed treatments that had been developed under the scheme went on to win EU marketing approval.

After achieving a landmark in gene-editing with NTLA-2001, Intellia moves to expand its reach into a larger market.

Daily notebook from the virtual J.P. Morgan Healthcare Conference: new immunotherapies coming, what the year could look like in deals and new updates from multiple Asian companies.